Welcome to our dedicated page for Natural Alternatives International news (Ticker: NAII), a resource for investors and traders seeking the latest updates and insights on Natural Alternatives International stock.
Natural Alternatives International, Inc. (NAI), headquartered in Carlsbad, California, is a prominent player in the nutritional supplements industry. Established in 1980, NAI specializes in the formulation, manufacturing, and marketing of customized nutritional supplements. The company's unique approach combines clinical research, science-based formulations, and advanced quality assurance testing methodologies to produce superior nutritional products. These are specifically designed to address various health conditions and meet the highest standards.
NAI operates through two primary segments: Private-Label Contract Manufacturing and Patent & Trademark Licensing. The majority of the company's revenue is derived from the Private-Label Contract Manufacturing segment, offering tailored manufacturing services to firms that market and distribute nutritional and healthcare products. The Patent & Trademark Licensing segment earns income through royalty agreements linked to the sale of licensed products, such as their proprietary CarnoSyn® beta-alanine.
In recent developments, NAI temporarily closed its new high-speed powder blending and packaging facility in Carlsbad due to an inventory rebalance by one of its largest customers. Despite this, the company remains optimistic about its long-term growth. For example, CarnoSyn® beta-alanine sales saw a significant increase, showing robust demand for its patented ingredients.
Financially, NAI reported net sales of $35.9 million in the fourth quarter of fiscal year 2023, marking a decrease from the prior year. This decline was primarily due to softened consumer demand and reduced orders as customers adjusted their inventory levels. However, the company saw a marked increase in CarnoSyn® beta-alanine sales, reflecting the strength of its patent and trademark licensing segment.
As of late 2023, NAI's financial health remains solid, with a working capital of $42.3 million and cash reserves of $16.7 million. The company continues to invest in relationship development and product innovation to drive future growth, confident in its ability to navigate current economic headwinds.
NAI's comprehensive partnership approach includes support services such as scientific research, clinical studies, regulatory compliance supervision, and marketing assistance. This holistic service model distinguishes NAI in the industry, making it a go-to partner for businesses looking for customized nutritional product solutions.
Natural Alternatives International (NAII) reported Q1 2025 financial results with a net loss of $2.0 million ($0.33 per share) on net sales of $33.2 million, compared to a net loss of $0.7 million in Q1 2024. Sales decreased 2.4% year-over-year, with private-label contract manufacturing down 4.8%. However, CarnoSyn® beta-alanine revenue increased 41.6% to $2.5 million. The company faced operational losses due to reduced sales, changes in sales mix, and increased manufacturing costs. As of September 30, 2024, NAII had $10.1 million in cash and $38.0 million in working capital, with $5.4 million in outstanding borrowings.
CarnoSyn® Brands and Natural Alternatives International (NAII) have announced a new distribution partnership with B&D Nutritional Ingredients, effective October 1st, 2024. Under the agreement, B&D will distribute NAI's new carnosine booster, TriBsyn™, to U.S.-based nutritional supplement, functional food, and beverage markets. TriBsyn™ is a patent-pending ingredient that increases beta-alanine bioavailability while eliminating paresthesia sensation. The product targets various consumer segments including older adults, vegetarians, and vegans seeking to boost their carnosine levels.
Natural Alternatives International (NAI) and CarnoSyn® Brands will showcase TriBsyn™, a patent-pending formula, at the 46th ESPEN Congress on Clinical Nutrition & Metabolism in Milan, Italy from September 7-10, 2024. TriBsyn™ utilizes proprietary technology to increase beta-alanine bioavailability and absorption while eliminating paresthesia associated with high doses of beta-alanine.
The team will be at stand #16 to discuss the latest clinical evidence of TriBsyn™, which offers opportunities for various consumer groups, including older adults and vegans. Aaron Starr, VP of CarnoSyn® Brands, highlighted the product's potential in addressing the growing demand for healthy aging and wellness solutions. The team will also attend the 20th European Geriatric Medicine Society Congress in Valencia, Spain on September 18-20.
Natural Alternatives International (NAI) has unveiled TriBsyn™, a revolutionary carnosine booster under its CarnoSyn® Brands portfolio. This groundbreaking product utilizes CarnoSyn® beta-alanine and patent-pending technology to increase beta-alanine bioavailability and absorption while eliminating paresthesia, a common side effect. TriBsyn™ improves beta-alanine absorption by more than four times compared to conventional forms, allowing for lower dosages and increased formulation flexibility.
The product aims to support general wellness, including cognitive performance, muscle function in older adults, and slowing age-related health decline. NAI plans to launch TriBsyn™ commercially at the 46th ESPEN Congress in Milan, Italy, in September. The company expects this innovation to strengthen its presence in dietary supplement categories and fortified and medical foods markets, particularly targeting the aging population and those with plant-based diets.
Natural Alternatives International (NAII) announced its fiscal 2024 Q3 results, revealing a net loss of $1.6 million, or ($0.27) per diluted share, on net sales of $25.1 million. This compares to a $2.4 million net loss in Q3 of the prior year. Q3 net sales fell by 23%, driven by a 26% decrease in private-label contract manufacturing sales. However, CarnoSyn® beta-alanine revenue rose 13% to $2.7 million. For the nine months ending March 31, 2024, NAII reported a net loss of $5.3 million on net sales of $84.3 million, a 29% decrease year-over-year. Cash reserves stood at $12.4 million, with zero outstanding on their credit facility. The company expects to report a net loss for Q4 and fiscal 2024 due to ongoing market adjustments but forecasts future sales growth and a return to profitability with the reopening of their Carlsbad facility in May 2024.
FAQ
What is the current stock price of Natural Alternatives International (NAII)?
What is the market cap of Natural Alternatives International (NAII)?
What does Natural Alternatives International, Inc. (NAI) specialize in?
How does NAI support its clients?
What are the primary business segments of NAI?
What recent challenges has NAI faced?
How did CarnoSyn® beta-alanine sales perform recently?
What is the financial condition of NAI?
Where is NAI headquartered?
What year was NAI founded?
What sets NAI apart from other companies in the industry?
What are NAI's future plans for growth?
